CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $80,128,453
- in 11 filings, $80.1M under 10b5-1 plans
Net −$80,128,453. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-15 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Sale 10b5-1 | −1,400 | $63.65 | $89K | 118,497 |
| 2026-09-15 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Sale 10b5-1 | −1,431 | $65.31 | $93K | 117,066 |
| 2026-09-15 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −39,283 | 18,217 | ||
| 2026-09-15 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −1,381 | 53,119 | ||
| 2026-09-15 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −36,526 | 28,474 | ||
| 2026-09-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 | +95,666 | $23.34 | $2.2M | 528,552 |
| 2026-09-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −63,498 | $61.99 | $3.9M | 465,054 |
| 2026-09-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −28,796 | $62.66 | $1.8M | 436,258 |
| 2026-09-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −3,102 | $63.64 | $197K | 433,156 |
| 2026-09-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −270 | $65.31 | $18K | 432,886 |
| 2026-09-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −95,666 | 304,334 | ||
| 2026-09-15 | ROTE WILLIAM E. Chief Research Officer | Option exercise 10b5-1 | +39,000 | $25.25 | $985K | 154,745 |
| 2026-09-15 | ROTE WILLIAM E. Chief Research Officer | Option exercise 10b5-1 | +39,650 | $17.96 | $712K | 194,395 |
| 2026-09-15 | ROTE WILLIAM E. Chief Research Officer | Sale 10b5-1 | −63,907 | $61.99 | $4.0M | 130,488 |
| 2026-09-15 | ROTE WILLIAM E. Chief Research Officer | Sale 10b5-1 | −29,021 | $62.66 | $1.8M | 101,467 |
| 2026-09-15 | ROTE WILLIAM E. Chief Research Officer | Sale 10b5-1 | −3,000 | $63.65 | $191K | 98,467 |
| 2026-09-15 | ROTE WILLIAM E. Chief Research Officer | Sale 10b5-1 | −270 | $65.31 | $18K | 98,197 |
| 2026-09-15 | ROTE WILLIAM E. Chief Research Officer | Option exercise · Employee stock option (right to buy) 10b5-1 | −39,000 | 0 | ||
| 2026-09-15 | ROTE WILLIAM E. Chief Research Officer | Option exercise · Employee stock option (right to buy) 10b5-1 | −39,650 | 350 | ||
| 2026-09-15 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise 10b5-1 | +37,500 | $15.46 | $580K | 142,889 |
Page 4 of 41 · 802 trades